

# CYGNUS<sup>®</sup>

## MAX XL

### INCREASING THE AVAILABLE ALLOGRAFT SIZE OF THE UMBILICAL CORD MEMBRANE



**CYGNUS Max XL are amniotic allografts processed to retain the inherent mechanical properties of amniotic tissue and rich supply of extracellular matrix, growth factors and cytokines.<sup>1,2</sup>**

#### ➤ **CYGNUS MAX XL FENESTRATED UMBILICAL CORD MEMBRANE FEATURES AND BENEFITS**

Amniotic-derived tissues may be used as a soft tissue barrier and wound covering that retains endogenous extracellular matrix (ECM), growth factors and cytokines<sup>2-5</sup> essential for signaling. The properties of amniotic tissue help provide mechanical protection<sup>6</sup> to damaged tissue while retaining nutrient-rich growth factors.<sup>7-9</sup> CYGNUS Max XL is comprised of fenestrated umbilical cord membrane, increasing the available allograft size to cover a larger wound while also allowing the wound to drain.

#### **FENESTRATED UMBILICAL CORD MEMBRANES**


- Thick amniotic membrane allograft (400µm or 0.4mm)
- Retains inherent extracellular matrix components, growth factors and cytokines
- Robust enough to be sutured in place
- Excellent handling properties

#### **CYGNUS MAX XL FENESTRATED UMBILICAL CORD MEMBRANE**

- 5-year shelf life for room temperature storage
- No upfront preparation – hydrates in site
- 4X thicker than amniotic membrane allografts
- Fenestration allows for the ability to increase the available size of the umbilical cord membrane allograft

#### **POTENTIAL CLINICAL APPLICATIONS**

- Spine & Neurosurgery
- Wound care
- Burn care
- Dermatology
- Oral Surgery
- Shoulder




## ▶ SAFE AND TRUSTED PARTNER

VIVEX Biologics is a regenerative solutions company, focusing on patient care through the innovation of tissue and biologic-based therapies in Wound Care, Ortho-Fusion and Interventional Pain. With more than 50 years of highly safe and effective operations, VIVEX aims to provide advanced regenerative solutions.



- Amniotic tissue is recovered from healthy mothers at live births.
- Handled and processed in accordance with both FDA regulations and AATB standards.
- VIVEX has distributed over 1 million allografts since 2010.
- No reported adverse events and no reported disease transmission.

## ▶ CORRECT ORIENTATION



## ▶ ORDERING INFORMATION

Product HCPCS Code: Q4170 (CYGNUS) per square centimeter

CODE	DESCRIPTION	SIZE	SQ. CM.
CAX020300S	CYGNUS® Max XL Fenestrated Umbilical Cord Membrane	2x3cm	6
CAX030300S	CYGNUS® Max XL Fenestrated Umbilical Cord Membrane	3x3cm	9
CAX030800S	CYGNUS® Max XL Fenestrated Umbilical Cord Membrane	3x8cm	24
CAX040400S	CYGNUS® Max XL Fenestrated Umbilical Cord Membrane	4x4cm	16
CAX040600S	CYGNUS® Max XL Fenestrated Umbilical Cord Membrane	4x6cm	24
CAX040800S	CYGNUS® Max XL Fenestrated Umbilical Cord Membrane	4x8cm	32
CAX050700S	CYGNUS® Max XL Fenestrated Umbilical Cord Membrane	5x7cm	35

VIVEX Biologics will use reasonable efforts to provide accurate and complete information herein, but this information should not be construed as providing clinical advice, dictating reimbursement policy or as a substitute for the judgment of a health care provider. It is the health care provider's responsibility to determine the appropriate treatment, codes, charges for services and use of modifiers for services rendered and to submit coverage or reimbursement-related documentation.

1. Rowlatt, U. (1979), Intrauterine wound healing in a 20-week human fetus. *Virchows Arch A Pathol Anat Histol*, 381(3), 353-361
2. Coolen, N.A. et al. (2010). Comparison between human fetal and adult skin. *Archives of Dermatological Research*, 302(1), 47-55.
3. Coolen NA, Schouten KC, Boekema BK, Middelkoop E, Ulrich MM. Wound healing in a fetal, adult, and scar tissue model: a comparative study. *Wound Repair Regen*. 2010;18(3):291-301. doi:10.1111/j.1524-475X.2010.00585.x.
4. Tseng SC, Espana EM, Kawakita T, et al. How does amniotic membrane work? *Ocul Surf*. 2004;2(3):177-187.
5. Riordan NH, George BA, Chandler TB, McKenna RW. Case report of non-healing surgical wound treated with dehydrated human amniotic membrane. *J Transl Med*. 2015;13:242. doi:10.1186/s12967-015-0608-8.
6. Kim SS, Sohn SK, Lee KY, et al. Use of human amniotic membrane wrap in reducing perineural adhesions in a rabbit model of ulnar nerve neurotaphy. *J Hand Surg Eur Vol*. 2010;35(3):214-219. doi:10.1177/1753193409352410.
7. Delcroix GJ, Namin S, D'Ippolito G, Temple HT, Marshall R. Preserving the natural regenerative potential of amniotic membrane. *VIVEX Biomedical*.
8. Niknejad H, Peirovi H, Jorjani M, et al. Properties of the amniotic membrane for potential use in tissue engineering. *Eur Cell Mater*. 2008;15:88-89.
9. Koob TJ, Lim JJ, Massee M, Zabek N, Denozière G. Properties of dehydrated human amnion/chorion composite grafts: implications for wound repair and soft tissue regeneration. *J Biomed Mater Res B Appl Biomater*. 2014;102(6):1353-1362. doi:10.1002/jbm.b.33141.



2430 NW 116th Street, Miami, FL 33167  
(888) 684-7783 | vivex.com | customercare@vivex.com  
Trademarks™ and Registered Trademarks® of 2021 VIVEX Biologics, Inc.  
Copyright © 2021 VIVEX Biologics, Inc. All rights reserved.

MKG-AWC-23 Rev. 01